Core Points - The company has decided not to adjust the conversion price of the "Shuyu Convertible Bonds" despite triggering conditions for downward adjustment due to stock prices falling below 85% of the conversion price [8][9] - The company will review the situation again if the conditions are triggered after a specified period [8][9] Company Overview - The company has a share buyback account holding 2,988,788 shares, representing 0.74% of the total share capital [4] - There have been no changes in the controlling shareholder or actual controller during the reporting period [6][7] Financial Information - The company does not plan to distribute cash dividends or issue bonus shares during the reporting period [3] - There are no preferred shareholders or related distributions reported for the period [8]

Group 1 - The core viewpoint of the article highlights the financial performance of Shuyupingmin, indicating a modest increase in revenue and a significant rise in net profit for the first half of 2025 [1] - The company's revenue for the first half of 2025 is approximately 4.881 billion yuan, reflecting a year-on-year increase of 1.3% [1] - The net profit attributable to shareholders is around 36.25 million yuan, showing a substantial year-on-year increase of 49.83% [1] - Basic earnings per share are reported at 0.09 yuan, which is a 50% increase compared to the previous year [1] Group 2 - As of the report, the market capitalization of Shuyupingmin stands at 4.9 billion yuan [2]

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-070 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 漱玉平民大药房连锁股份有限公司（以下简称"公司"）第四届董事会第九次会议于 2025 年 8 月 27 日在公司会议室以现场结合通讯表决的方式召开。会议通知已于 2025 年 8 月 16 日以书面、电子邮件等方式送达各位董事，会议应到董事 9 人，实到董事 9 人，其中董事 隋熠先生、杨策先生、独立董事赵振基先生、李文明先生以通讯表决方式出席。公司监事 和高级管理人员列席了本次会议。会议由公司董事长李文杰先生主持，本次会议召开符合 《中华人民共和国公司法》及《漱玉平民大药房连锁股份有限公司章程》等有关规定。 二、董事会会议审议情况 1、审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 国证券报》《上海证券报》《证券日报》上。 ...

东兴证券股份有限公司 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于 | | | 防止关联方占用公司资源的制度、募集资金管理制度、 | 是 | | 内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6 次 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4.公司治理督导情况 | | | （1）列席公司股东大会次数 | 次 0 | | （2）列席公司董事会次数 | 1 次 | | （3）列席公司监事会次数 | 次 1 | | 5.现场检查情况 | | | （1）现场检查次数 | 无，拟于下半年开展 | | （2）现场检查报告是否按照本所规定报送 | 不适用 | | （3）现场检查发现的 ...

Core Viewpoint - The company reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating positive financial performance despite modest revenue growth [1] Financial Performance - The company achieved an operating revenue of 4.881 billion yuan, representing a year-on-year growth of 1.30% [1] - The net profit attributable to shareholders was 36.2509 million yuan, showing a year-on-year increase of 49.83% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 31.5454 million yuan, reflecting a year-on-year growth of 24.63% [1] - The basic earnings per share were reported at 0.09 yuan [1]

漱玉平民大药房连锁股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司 的关联关系 | 上市公司核 算的会计科 目 | 2025 年期 初占用资 金余额 | 2025 年上 半年占用 累计发生 金额（不含 利息） | 2025 年上 2025 年上 半年占用 半年偿还 资金的利 累计发生 息（如有） 金额 | 2025 年上半 年期末占用 资金余额 | 占用形 成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 冠县鑫鑫民大药店连锁有限公司 | | 本公司控股子公司 | 其他应收款 | 21.10 | 16.08 | 3.30 | 33.88 | 代垫款 | 经营性往来 | | 河南复生堂医药有限公司 | | 本公司控股子公司 | 其他应收款 | 22.69 | 8.49 | | 31.18 | 代垫款 | 经营性往来 | | 烟台统一大药房有限公司 | | 本公司控股子公司 | 其他应收款 | 10.90 | 18.69 ...

一、募集资金基本情况 （一）募集资金到位情况 经中国证券监督管理委员会《关于同意漱玉平民大药房连锁股份有限公司向不特定对 象发行可转换公司债券注册的批复》（证监许可〔2022〕2869 号）核准，公司向不特定对 象发行面值总额 8.00 亿元可转换公司债券，期限 6 年，每张面值 100 元，共计 800.00 万 张，募集资金总额为人民币 800,000,000.00 元，扣除发行费用人民币 9,415,851.41 元（不 含增值税）后，实际募集资金净额为人民币 790,584,148.59 元。 | 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-074 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 根据《上市公司募集资金监管规则》及《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定，漱玉平民大药房连锁 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-075 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 本次会计政策变更是漱玉平民大药房连锁股份有限公司（以下简称"公司"）根据中华 人民共和国财政部（以下简称"财政部"）修订的相关会计准则及规定要求进行的变更，不 属于公司自主变更会计政策的情形，不会对公司当期的财务状况、经营成果和现金流量产 生重大影响。本次会计政策变更是公司根据法律法规和国家统一的会计制度要求进行的变 更，无需提交公司董事会和股东大会审议批准。 二、本次会计政策变更的内容 本次会计政策变更前，公司执行财政部发布的《企业会计准则——基本准则》和各项 具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他相关规定执行。 （三）变更后公司采取的会计政策 本次会计政策变更后，公司将按照财政部发布的《企业会计准则解释第 18 号》要求执 行。除上述政策变更 ...

二、监事会会议审议情况 1、审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 监事会认为，《2025 年半年度报告》全文及其摘要真实反映了公司 2025 年半年度的财 务状况和经营成果，编制程序符合相关法律法规、中国证券监督管理委员会和深圳证券交 易所的相关规定，报告内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 | 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-071 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 表决结果：同意 3 票；反对 0 票；弃权 0 票。 漱玉平民大药房连锁股份有限公司 第四届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、监事会会议召开情况 漱玉平民大药房连锁股份有限公司（以下简称"公司"）第四届监事会第六次会议于 2025 年 8 月 27 日在公司会议室以现场表决的方式召开。会议通知及会议资料已于 2025 年 8 月 16 日以书面、电子邮件等方式送达各位监事。会议由监事会主席孟鹏女 ...

Financial Performance - The company's operating revenue for the first half of 2025 was RMB 4,881,231,520.65, representing a 1.30% increase compared to RMB 4,818,451,965.65 in the same period last year[19]. - Net profit attributable to shareholders increased by 49.83% to RMB 36,250,872.12 from RMB 24,195,275.81 year-on-year[19]. - The net cash flow from operating activities surged by 3,456.55% to RMB 137,846,170.86, compared to RMB 3,875,842.39 in the previous year[19]. - Basic and diluted earnings per share both rose by 50.00% to RMB 0.09 from RMB 0.06 in the same period last year[19]. - Total assets at the end of the reporting period reached RMB 9,841,614,859.75, marking a 6.13% increase from RMB 9,273,192,681.97 at the end of the previous year[19]. - The net assets attributable to shareholders increased by 1.23% to RMB 2,065,441,560.88 from RMB 2,040,366,110.44 at the end of the previous year[19]. - The company reported a significant increase in non-recurring gains and losses, totaling RMB 4,705,467.96 after tax adjustments[24]. - The company’s gross profit margin improved by 3.45% compared to the second half of 2024[35]. - The company reported a total revenue of 1,800 million for the quarter, reflecting a significant increase compared to the previous period[135]. - The net profit for the first half of 2025 was ¥30,524,685.35, compared to ¥16,037,713.14 in the first half of 2024, indicating a significant increase of approximately 90%[186]. Cash Flow and Investments - Cash used in investing activities saw a drastic decline of 2,116.19%, amounting to approximately -¥576.48 million, primarily due to increased acquisition payments[61]. - The net cash position decreased by 759.62% to approximately -¥307.15 million, attributed to higher acquisition payments during the reporting period[61]. - The company reported a significant increase in cash generated from operating activities, rising by 3,456.55% to approximately ¥137.85 million from ¥3.88 million in the previous year[61]. - The net cash flow from investing activities for the first half of 2025 is -CNY 576,478,537.73, compared to a positive CNY 28,592,507.16 in the same period of 2024, indicating increased investment outflows[192]. - The cash flow from financing activities in the first half of 2025 is CNY 131,480,134.67, a significant increase from CNY 14,096,753.65 in the previous year[192]. Operational Efficiency - The company optimized its cost structure, achieving a year-on-year improvement in the expense-to-sales ratio by 1.16%[35]. - The company has implemented a centralized procurement model combined with regional procurement to meet store operational needs[32]. - The company is implementing an SRM system to enhance supplier management and business integration, expected to be fully operational by the end of 2025[47]. - The company has established a comprehensive training system, achieving high qualification rates for new employee training and enhancing the capabilities of the management team[58]. - The company has optimized its accounts receivable management, resulting in a 3.01% decrease in accounts receivable to approximately ¥1.05 billion[68]. Market Expansion and Strategy - The company plans to diversify its product offerings, including health products, healthcare products, and medical devices, to meet consumer demand[35]. - The company is exploring diversified development by transforming from traditional pharmacies to health experience centers, expanding product categories and store types[56]. - The company is adopting a "new openings + mergers + cooperation + franchising" strategy to expand its store network, aiming to deepen penetration in mature areas and establish brand recognition in emerging markets[96]. - The company is actively exploring multi-channel sales systems and innovative pharmacy formats to enhance its comprehensive competitiveness[96]. - The company has plans to continue expanding its market presence, focusing on new product development and technological advancements to drive future growth[199]. Risk Management - The company is facing various risks, including macroeconomic and market risks, which are detailed in the management discussion section[5]. - The company emphasizes the importance of investor awareness regarding potential investment risks associated with forward-looking statements[5]. - The company has developed a risk control platform covering 17 cities and 22 companies, with a risk rule library comprising over 30,000 rules[54]. - The company is facing risks from industry policy changes and market competition, necessitating a robust policy tracking and compliance system[94][95]. - The company has established a research group to analyze policy changes and ensure compliance with evolving regulations in the pharmaceutical retail industry[94]. Shareholder and Equity Information - The company has not distributed cash dividends or bonus shares for the half-year period, nor has it increased share capital from capital reserves[103]. - A total of 1.63205 million shares of restricted stock have been canceled due to unfulfilled performance conditions and changes in the status of incentive recipients[104]. - The total number of common shareholders at the end of the reporting period was 14,100[151]. - Li Wenjie holds 35.17% of shares, totaling 142,560,000 shares, with 58,100,000 shares pledged[151]. - The company has 162,000,000 restricted shares, representing 39.97% of total shares, which remain unchanged during the reporting period[148]. Corporate Social Responsibility - The company has conducted 31 public welfare activities during the reporting period, donating over 1.17 million yuan to social causes[106]. - The company launched the "Big Tree Project" in collaboration with Qilu Evening News and 21 industrial brands, aiming to support underprivileged students in Shandong Province over the next three years[107]. - The company has been actively involved in rural revitalization efforts, supporting improvements in rural medical conditions and empowering farmers through e-commerce initiatives[108]. - The company has established a sustainable public welfare ecosystem centered around the "Shuyu Public Welfare Home" platform, enhancing its brand reputation and social influence[107]. Future Outlook - The company has provided a future outlook with a revenue guidance of 2,500 million for the next quarter, representing a 15% increase from the current quarter[135]. - New product launches are expected to contribute an additional 500 million in revenue over the next fiscal year[135]. - Market expansion plans include entering three new regions, projected to increase market share by 10%[135]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 1,800 million allocated for potential deals[135].